These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 11544272)
21. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
22. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858 [TBL] [Abstract][Full Text] [Related]
23. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Chen CH; Wang TL; Hung CF; Yang Y; Young RA; Pardoll DM; Wu TC Cancer Res; 2000 Feb; 60(4):1035-42. PubMed ID: 10706121 [TBL] [Abstract][Full Text] [Related]
24. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545 [TBL] [Abstract][Full Text] [Related]
25. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071 [TBL] [Abstract][Full Text] [Related]
26. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Wang TL; Ling M; Shih IM; Pham T; Pai SI; Lu Z; Kurman RJ; Pardoll DM; Wu TC Gene Ther; 2000 May; 7(9):726-33. PubMed ID: 10822298 [TBL] [Abstract][Full Text] [Related]
27. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201 [TBL] [Abstract][Full Text] [Related]
28. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy. Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722 [TBL] [Abstract][Full Text] [Related]
29. Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis. Cheng WF; Chen LK; Chen CA; Chang MC; Hsiao PN; Su YN; Lee CN; Jeng HJ; Hsieh CY; Sun WZ Mol Ther; 2006 Jan; 13(1):203-10. PubMed ID: 16140583 [TBL] [Abstract][Full Text] [Related]
30. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037 [TBL] [Abstract][Full Text] [Related]
31. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264 [TBL] [Abstract][Full Text] [Related]
32. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules. Li H; Ou X; Xiong J Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598 [TBL] [Abstract][Full Text] [Related]
33. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231 [TBL] [Abstract][Full Text] [Related]
34. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. Ruan Z; Yang Z; Wang Y; Wang H; Chen Y; Shang X; Yang C; Guo S; Han J; Liang H; Wu Y J Immunother; 2009 Jun; 32(5):486-91. PubMed ID: 19609240 [TBL] [Abstract][Full Text] [Related]
35. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048 [TBL] [Abstract][Full Text] [Related]
36. [The construction and immune response of fusion DNA vaccine CRT180/HPV6E7]. Zhao KJ; Cheng H; Xu Y; Zhu KJ; Chen ML; Zhang X; Song T; Wang Q; Chen DF Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 38(4):573-7. PubMed ID: 17718414 [TBL] [Abstract][Full Text] [Related]
37. [Immunogenicity of mutant and wild HPV16 DNA vaccines]. Zuo YG; Wang JB; Jin HZ; Yue-hua L Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Oct; 26(5):554-7. PubMed ID: 15562771 [TBL] [Abstract][Full Text] [Related]
38. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Wlazlo AP; Deng H; Giles-Davis W; Ertl HC Cancer Gene Ther; 2004 Jun; 11(6):457-64. PubMed ID: 15118761 [TBL] [Abstract][Full Text] [Related]